Organon & Co
OGN7.185USD
+0.095+1.34%
Handelsschluss 12/26, 16:00（ET）Kurse um 15 Minuten verzögert
1.87BMarktkapitalisierung
3.72KGV TTM
mehr Informationen über Organon & Co Unternehmen
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Organon & Co Informationen
BörsenkürzelOGN
Name des UnternehmensOrganon & Co
IPO-datumMay 14, 2021
CEOMorrissey (Joseph T)
Anzahl der mitarbeiter10000
WertpapierartOrdinary Share
GeschäftsjahresendeMay 14
Addresse30 Hudson Street
StadtJERSEY CITY
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl07302
Telefon15514306000
Websitehttps://www.organon.com/
BörsenkürzelOGN
IPO-datumMay 14, 2021
CEOMorrissey (Joseph T)
Führungskräfte von Organon & Co
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%
Nach RegionUSD
Name
Umsatz
Anteil
Europe and Canada
419.00M
26.29%
United States
414.00M
25.97%
Latin America, Middle East, Russia and Africa
285.00M
17.88%
Asia Pacific and Japan
250.00M
15.68%
China
204.00M
12.80%
Other
22.00M
1.38%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
Andere
65.33%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
Andere
65.33%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
47.62%
Investment Advisor/Hedge Fund
20.77%
Hedge Fund
4.75%
Pension Fund
2.56%
Research Firm
2.06%
Bank and Trust
0.92%
Sovereign Wealth Fund
0.86%
Individual Investor
0.36%
Venture Capital
0.04%
Andere
20.06%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
1485
219.88M
84.58%
-37.41M
2025Q2
1527
205.34M
78.98%
-50.49M
2025Q1
1611
213.21M
82.04%
-52.34M
2024Q4
1647
218.39M
84.67%
-40.43M
2024Q3
1625
211.80M
82.26%
-47.57M
2024Q2
1676
208.67M
81.14%
-51.47M
2024Q1
1700
205.29M
80.30%
-45.21M
2023Q4
1767
202.90M
79.38%
-24.07M
2023Q3
1835
205.61M
80.45%
-25.35M
2023Q2
2016
205.94M
80.75%
-21.55M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
32.15M
12.37%
+2.54M
+8.57%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
28.28M
10.88%
-627.34K
-2.17%
Jun 30, 2025
MFS Investment Management
10.11M
3.89%
-469.39K
-4.44%
Jun 30, 2025
State Street Investment Management (US)
9.52M
3.66%
+540.48K
+6.02%
Jun 30, 2025
LSV Asset Management
7.99M
3.07%
+8.69K
+0.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.40M
1.69%
-121.50K
-2.69%
Jun 30, 2025
Millennium Management LLC
9.09M
3.5%
+8.11M
+829.74%
Jun 30, 2025
AQR Capital Management, LLC
3.25M
1.25%
+1.88M
+136.10%
Jun 30, 2025
Gotham Asset Management, LLC
2.71M
1.04%
+1.31M
+93.22%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.63M
1.78%
+459.24K
+11.02%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
State Street SPDR S&P Pharmaceuticals ETF
1.72%
Alger Russell Innovation ETF
1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.22%
First Trust Health Care Alphadex Fund
1.1%
Invesco S&P SmallCap Health Care ETF
1.07%
Brandes US Small-Mid Cap Value ETF
1.05%
iShares U.S. Pharmaceuticals ETF
0.65%
Lattice Hartford Multifactor Small Cap ETF
0.5%
WisdomTree U.S. SmallCap Dividend Fund
0.5%
Royce Quant Small-Cap Quality Value ETF
0.45%
Mehr Anzeigen
State Street SPDR S&P Pharmaceuticals ETF
Anteil1.72%
Alger Russell Innovation ETF
Anteil1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.22%
First Trust Health Care Alphadex Fund
Anteil1.1%
Invesco S&P SmallCap Health Care ETF
Anteil1.07%
Brandes US Small-Mid Cap Value ETF
Anteil1.05%
iShares U.S. Pharmaceuticals ETF
Anteil0.65%
Lattice Hartford Multifactor Small Cap ETF
Anteil0.5%
WisdomTree U.S. SmallCap Dividend Fund
Anteil0.5%
Royce Quant Small-Cap Quality Value ETF
Anteil0.45%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
1.03B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Nov 10, 2025
OGN.NB Final Cash Dividend of gross USD 0.02 paid on Dec 11, 2025 going ex on Nov 20, 2025
Nov 20, 2025
Dec 11, 2025
Nov 20, 2025
Aug 05, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Sep 11, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 11, 2025
Aug 15, 2025
May 01, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Jun 12, 2025 going ex on May 12, 2025
May 12, 2025
Jun 12, 2025
May 12, 2025
Feb 13, 2025
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025
Feb 24, 2025
Mar 13, 2025
Feb 24, 2025
Oct 31, 2024
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024
Nov 12, 2024
Dec 12, 2024
Nov 12, 2024
Aug 06, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 12, 2024
Aug 16, 2024
May 02, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024
May 13, 2024
Jun 13, 2024
May 10, 2024
Feb 15, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024
Feb 26, 2024
Mar 14, 2024
Feb 23, 2024
Nov 02, 2023
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023
Nov 13, 2023
Dec 14, 2023
Nov 10, 2023
Aug 08, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 14, 2023
Aug 17, 2023
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Organon & Co?
Die fünf größten Anteilseigner von Organon & Co sind:
The Vanguard Group, Inc. hält 32.15M Aktien, was 12.37% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 28.28M Aktien, was 10.88% der Gesamtaktien entspricht.
MFS Investment Management hält 10.11M Aktien, was 3.89% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 9.52M Aktien, was 3.66% der Gesamtaktien entspricht.
LSV Asset Management hält 7.99M Aktien, was 3.07% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 32.15M Aktien, was 12.37% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 28.28M Aktien, was 10.88% der Gesamtaktien entspricht.
MFS Investment Management hält 10.11M Aktien, was 3.89% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 9.52M Aktien, was 3.66% der Gesamtaktien entspricht.
LSV Asset Management hält 7.99M Aktien, was 3.07% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Organon & Co?
Die drei wichtigsten Anteilseigner-Typen von Organon & Co sind:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
MFS Investment Management
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
MFS Investment Management
Wie viele Institutionen halten Anteile an Organon & Co (OGN)?
Mit Stand vom 2025Q3 halten 1485 Institutionen Anteile an Organon & Co, mit einem Gesamtmarktwert von etwa 219.88M, was 84.58% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um 5.59% gestiegen.
Was ist die größte Einnahmequelle von Organon & Co?
Am FY2025Q2 erzielte das Geschäft mit Women’s Health für Organon & Co den höchsten Umsatz in Höhe von 462.00M, was 28.98% des Gesamtumsatzes entspricht.
